Updated Colonoscopy Services 2 Feb 2018 (PDF 309 KB)
Updated Colonoscopy Services 2 Feb 2018 (Word 493 KB)
The 1 March 2018 commencement date for new MBS colonoscopy items is changing. Existing MBS items (32090 and 32093) should be used until further notice. This will ensure patients continue to have access to Medicare-funded colonoscopy services.
The changes to colonoscopy services announced in August 2017 recognise that clinical practice and professional standards have shifted over time and the new items were designed to be well supported by the NHMRC Clinical Guidelines for Surveillance Colonoscopy. These guidelines are currently being revised and are anticipated to be released in late 2018.
The Government remains committed to an improved suite of colonoscopy items and to ensure as smooth a transition to the new arrangements as possible, the MBS Review Taskforce has been invited to provide further advice.
Stakeholders will be advised in advance of any changes to the MBS items for colonoscopy.
What do the changes involve?
MBS items for colonoscopy 32090 and 32093 will be replaced by 20 new MBS items that better describe the indications for initial colonoscopy and ensure appropriate surveillance intervals of patients at increased risk of developing colorectal cancer. The new items also define the examination of the colon ‘to the caecum’ to ensure that a comprehensive examination is performed.
Claiming restrictions will apply with other colonoscopy services (same day, same patient, same practitioner).
Why is the Government making this change?
These changes are intended to address significant national variation in per capita use of colonoscopy that cannot be explained by clinical or patient demographic factors. These changes are based on recommendations of the Medicare Benefits Schedule Review Taskforce.
Change to item description/fees:
Items to be deleted from the MBS:
32090, 32093
Draft new items on the MBS (final wording of items subject to finalisation and passage of legislation):
32222 | Endoscopic examination of the colon to the caecum by COLONOSCOPY with or without biopsy.
ˇ For patient following a positive faecal occult blood test, not being a service associated with a service to which items 32088, 32089 applies (National Bowel Cancer Screening Program participants) and items 32223 to 32240 applies
Payable not more than once every 2 years (Anaes.)
Fee: $334.35 Benefit: 75% = $250.80 85% = $284.20 |
32223 | Endoscopic examination of the colon to the caecum by COLONOSCOPY with or without biopsy
Not being a service associated with a service to which items 32222, 32224 to 32240 applies (Anaes.)
Fee: $334.35 Benefit: 75% = $250.80 85% = $284.20 |
32224 | Endoscopic examination of the colon to the caecum by COLONOSCOPY with or without biopsy
ˇ For patient following surgery for colorectal cancer
Not being a service associated with a service to which items 32222, 32223, 32225 to 32240 applies (Anaes.)
Fee: $334.35 Benefit: 75% = $250.80 85% = $284.20 |
32225 | Endoscopic examination of the colon to the caecum by COLONOSCOPY with or without biopsy
ˇ For patient with MODERATE risk of colorectal cancer due to family history of colorectal cancer (1 first degree relative < 55yrs at diagnosis OR 2 first degree relatives OR 1 first degree relative and 1 second degree relative on the same side of the family, any age at diagnosis)
Not being a service associated with a service to which items 32222 to 32224 and 32226 to 32240 applies (Anaes.)
Payable not more than once every 5 years
Fee: $334.35 Benefit: 75% = $250.80 85% = $284.20 |
32226 | Endoscopic examination of the colon to the caecum by COLONOSCOPY with or without biopsy
ˇ For patient with HIGH risk of colorectal cancer due to known or suspected familial condition including FAP or Lynch Syndrome
Not being a service associated with a service to which items 32222 to 32225 and 32227 to 32240 applies (Anaes.)
Payable not more than once every 12 months
Fee: $334.35 Benefit: 75% = $250.80 85% = $284.20 |
32227 | Endoscopic examination of the colon to the caecum by COLONOSCOPY with or without biopsy
ˇ For patient with previous history of 1-2 adenomas AND all <10mm, no villous features, no high grade dysplasia; OR
ˇ For patient with inflammatory bowel disease, Group 3 (ulcerative colitis without high risk features when two previous colonoscopies are macroscopically inactive and histologically negative for dysplasia)
Not being a service associated with a service to which items 32222 to 32226 and 32228 to 32240 applies (Anaes.)
Payable not more than once every 5 years
Fee: $334.35 Benefit: 75% = $250.80 85% = $284.20 |
32228 | Endoscopic examination of the colon to the caecum by COLONOSCOPY with or without biopsy
ˇ For patient with previous history of 3-4 adenomas, sessile serrated OR any adenoma >10mm, villous features, high grade dysplasia; OR
ˇ For patient with inflammatory bowel disease, Group 2 (quiescent ulcerative colitis without high risk features)
Not being a service associated with a service to which items 32222 to 32227 and 32229 to 32240 applies (Anaes.)
Payable not more than once every 3 years
Fee: $334.35 Benefit: 75% = $250.80 85% = $284.20 |
32229 | Endoscopic examination of the colon to the caecum by COLONOSCOPY with or without biopsy
(i) For patient with previous history of 5-9 adenomas; OR
(ii) For patient with inflammatory bowel disease, Group 1 (any high risk feature including:
ˇ Chronically active ulcerative colitis
ˇ Primary sclerosing cholangitis
ˇ Colorectal cancer in first degree relative at <50y age
ˇ Stricture, multiple inflammatory polyps or shortened colon
ˇ Previous dysplasia)
Not being a service associated with a service to which items 32222 to 32228 and 32230 to 32240 applies (Anaes.)
Payable not more than once every 12 months
Fee: $334.35 Benefit: 75% = $250.80 85% = $284.20 |
32230 | Endoscopic examination of the colon to the caecum by COLONOSCOPY with or without biopsy
ˇ For patient with previous history of >10 adenomas or incomplete excision of large, sessile adenoma
Not being a service associated with a service to which items 32222 to 32229 and 32231 to 32240 applies (Anaes.)
Payable not more than 4 times per year
Fee: $334.35 Benefit: 75% = $250.80 85% = $284.20 |
32231 | Endoscopic examination of the colon to the caecum by COLONOSCOPY with or without biopsy
ˇ For failed preparation of the colon
Not being a service associated with a service to which items 32222 to 32230 and 32232 to 32240 applies (Anaes.)
Fee: $334.35 Benefit: 75% = $250.80 85% = $284.20 |
32232 | Endoscopic examination of the colon to the caecum by COLONOSCOPY for the REMOVAL OF 1 OR MORE POLYPS,
ˇ For patient following a positive faecal occult blood test, not in association with items 32088, 32089 for National Bowel Cancer Screening Program participants
Not being a service associated with a service to which items 32222 to 32231 and 32233 to 32240 applies (Anaes.)
Payable no more than once every 2 years
Fee: $469.20 Benefit: 75% = $351.90 85% = $398.85 |
32233 | Endoscopic examination of the colon to the caecum by COLONOSCOPY for the REMOVAL OF 1 OR MORE POLYPS,
Not being a service associated with a service to which items 32222 to 32232 and 32234 to 32240 applies (Anaes.)
Fee: $469.20 Benefit: 75% = $351.90 85% = $398.85 |
32234 | Endoscopic examination of the colon to the caecum by COLONOSCOPY for the REMOVAL OF 1 OR MORE POLYPS,
ˇ For patient following surgery for colorectal cancer
Not being a service associated with a service to which items 32222 to 32233 and 32235 to 32240 applies (Anaes.)
Fee: $469.20 Benefit: 75% = $351.90 85% = $398.85 |
32235 | Endoscopic examination of the colon to the caecum by COLONOSCOPY for the REMOVAL OF 1 OR MORE POLYPS,
ˇ For patient with MODERATE risk of colorectal cancer due to family history of colorectal cancer (1 first degree relative <55yrs at diagnosis OR 2 first degree relatives OR 1 first degree relative and 1 second degree relative on the same side of the family, any age at diagnosis)
Not being a service associated with a service to which items 32222 to 32234 and 32236 to 32240 applies (Anaes.)
Fee: $469.20 Benefit: 75% = $351.90 85% = $398.85 |
32236 | Endoscopic examination of the colon to the caecum by COLONOSCOPY for the REMOVAL OF 1 OR MORE POLYPS,
ˇ For patient with a HIGH risk of colorectal cancer due to known or suspected familial condition including FAP or Lynch Syndrome
Not being a service associated with a service to which items 32222 to 32235 and 32237 to 32240 applies (Anaes.)
Fee: $469.20 Benefit: 75% = $351.90 85% = $398.85 |
32237 | Endoscopic examination of the colon to the caecum by COLONOSCOPY for the REMOVAL OF 1 OR MORE POLYPS or LESIONS,
ˇ For patient with previous history of 1-2 adenomas AND all <10mm, no villous features, no high grade dysplasia; OR
ˇ For patient with inflammatory bowel disease, Group 3 (ulcerative colitis without high risk features when two previous colonoscopies are macroscopically inactive and histologically negative for dysplasia)
Not being a service associated with a service to which items 32222 to 32236 and 32238 to 32240 applies (Anaes.)
Fee: $469.20 Benefit: 75% = $351.90 85% = $398.85 |
32238 | Endoscopic examination of the colon to the caecum by COLONOSCOPY for the REMOVAL OF 1 OR MORE POLYPS or LESIONS
ˇ For patient with previous history of 3-4 adenomas or any adenoma >10mm, villous features, high grade dysplasia; sessile serrated OR
ˇ For patient with inflammatory bowel disease, Group 2 (quiescent ulcerative colitis without high risk features)
Not being a service associated with a service to which items 32222 to 32237 and 32239 to 32240 applies (Anaes.)
Fee: $469.20 Benefit: 75% = $351.90 85% = $398.85 |
32239 | Endoscopic examination of the colon to the caecum by COLONOSCOPY for the REMOVAL OF 1 OR MORE POLYPS or LESIONS
(i) For patient with previous history of 5-9 adenomas, OR
(ii) For patient with inflammatory bowel disease, Group 1 (any high risk feature including:
ˇ Chronically active ulcerative colitis
ˇ Primary sclerosing cholangitis
ˇ Colorectal cancer in first degree relative at <50y age
ˇ Stricture, multiple inflammatory polyps or shortened colon
ˇ Previous dysplasia)
Not being a service associated with a service to which items 32222 to 32238 and 32240 applies (Anaes.)
Fee: $469.20 Benefit: 75% = $351.90 85% = $398.85 |
32240 | Endoscopic examination of the colon to the caecum by COLONOSCOPY for the REMOVAL OF 1 OR MORE POLYPS,
ˇ For patient with previous history of >10 adenomas, or incomplete excision of large or sessile adenoma
Not being a service associated with a service to which items 32222 to 322239 applies (Anaes.)
Fee: $469.20 Benefit: 75% = $351.90 85% = $398.85 |
32241 | Endoscopic examination of the colon by COLONOSCOPY for the treatment of radiation proctitis, angiodysplasia or post-polypectomy bleeding, 1 or more of, not a service association with a service to which item 32212 applies (Anaes.)
Fee: $469.20 Benefit: 75% = $351.90 85% = $398.85 |
Explanatory Note
Gastrointestinal Endoscopic Procedures - (Items 30473 to 30481, 30484 to 30487, 30490 to 30494, 30680 to 32023, 32084 to 32095, 32103, 32104 and 32106, 32222 to 32241)
The following are guidelines for appropriate minimum standards for the performance of GI endoscopy in relation to (a) cleaning, disinfection and sterilisation procedures, and (b) anaesthetic and resuscitation equipment.
These guidelines are based on the advice of the Gastroenterological Society of Australia, the Sections of HPB and Upper GI and of Colon and Rectal Surgery of the Royal Australasian College of Surgeons, and the Colorectal Surgical Society of Australia.
Cleaning, disinfection and sterilisation procedures
Endoscopic procedures should be performed in facilities where endoscope and accessory reprocessing protocols follow procedures outlined in:
1. Infection and Endoscopy (3rd edition), Gastroenterological Society of Australia;
2. Australian Guidelines for the Prevention and Control of Infection in Healthcare (NHMRC, 2010);
3. Australian Standard AS 4187-1994 (and Amendments), Standards Association of Australia.
Anaesthetic and resuscitation equipment
Where the patient is anaesthetised, anaesthetic equipment, administration and monitoring, and post-operative and resuscitation facilities should conform to the standards outlined in 'Guidelines on Sedation and/or Analgesia for Diagnostic and Interventional Medical, Dental or Surgical Procedures' (PS09), Australian & New Zealand College of Anaesthetists, Gastroenterological Society of Australia and Royal Australasian College of Surgeons.
Conjoint Committee
For the purposes of Item 32023, the procedure is to be performed by a colorectal surgeon or gastroenterologist with endoscopic training who is recognised by the Conjoint Committee for the Recognition of Training in Gastrointestinal Endoscopy.
New Colonoscopy Items
MBS items for colonoscopy have been revised to align MBS reimbursement with National Health and Medical Research Council (NHMRC) clinical guidelines:
ˇ NHMRC Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer
ˇ NHMRC Clinical Practice Guidelines for Surveillance Colonoscopy – in adenoma follow-up; following curative resection of colorectal cancer; and for cancer surveillance in inflammatory bowel disease
ˇ NHMRC Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer: A Guide for General Practitioners
These national guidelines do not support the use of colonoscopy for patients at average or slightly above average risk of colorectal cancer who do not have symptoms or a positive FOBT.
The Cancer Council of Australia, the Gastroenterological Society of Australia and the Colorectal Surgical Society of Australia and New Zealand have endorsed the following algorithms designed to be used in conjunction with the NHMRC approved guidelines:
Colonoscopic Surveillance Intervals – Adenomas. 2013,
Colonoscopic Surveillance Intervals – Following Surgery for Colorectal Cancer. 2013
Colorectal Cancer Screening – Family History. 2013, and
Colonoscopic Surveillance Intervals – Inflammatory Bowel Disease. 2013
For more information see the colorectal cancer pages on the Cancer Council Australia website
Timing of colonoscopy following polypectomy should conform to the recommended surveillance intervals set out in the endorsed algorithms, taking into account individualised risk assessment. In the absence of reliable clinical history, clinicians should use their best clinical judgement to determine the interval between testing and the item that best suits the condition of the patient.
All patients who require a colonoscopy will receive a service. However, MBS rebates will not be payable for services which do not meet the clinical indications and the item requirements for a colonoscopy or a repeat colonoscopy where the interval is specified in the item. Practitioners should ensure that their practice conforms to the approved clinical guidelines
Definition of previous history
For items 32227 to 32230 and 32237 to 32240 the most appropriate item to be billed is determined by the previous history of the patient. The previous history for the purpose of these items is defined by number, size and type of adenomas removed during the most recent prior colonoscopy.
Diagnostic colonoscopy Items 32222 to 32231
Diagnostic colonoscopy items 32222, 32225 to 32230 have mandated intervals for repeat surveillance testing as clinically recommended in the approved guidelines and algorithms. These services are payable under Medicare only when provided in accordance with the approved intervals.
For item 32227 to 32230 the patient’s previous history is used to determine the appropriate item to bill. In the absence of reliable patient history or evidence the practitioner should be guided by their best clinical judgement (see examples below).
Therapeutic colonoscopy Items 32232 to 32241
Therapeutic colonoscopy items 32233 and 32235 to 32240 do not have mandated intervals for repeat surveillance testing. However, services should conform to the recommended surveillance intervals set out in the endorsed algorithms, taking into account individualised risk assessment. Service patterns by individual practitioners may be subject to audit and peer review assessment.
For item 32237 to 32240 the patient’s previous history is used to determine the appropriate item to bill. In the absence of reliable patient history or evidence the practitioner should be guided by their best clinical judgement (see examples below)
Colonoscopy following surgery for colorectal cancer
Items 32224 and 32234 should only be used following surgery for colorectal cancer. Subsequent follow-ups should be billed under the most appropriate item. The guidelines and algorithms recommend that surveillance intervals following surgery for colorectal cancer will differ depending on if the colon was cleared of adenomas and synchronous cancers pre-operatively. If the colon was cleared then colonoscopy should be performed at 1 year post-op. If not, colonoscopy should be performed at 3-6 months post-op. The subsequent colonoscopic interval and items to bill will be dependent on the findings at these follow-ups. If results are normal a 5 yearly repeat is recommended. Where adenomas are found the number of adenomas will determine the interval surveillance in accordance with the guidelines and algorithms. For items 32224 and 32234, service patterns by individual practitioners may be subject to audit and peer review assessment. Follow-up of rectal cancers with examination of the rectum by digital examination, sigmoidoscopy or endorectal ultrasound should be considered independent of colonoscopic surveillance.
Colonoscopy for symptomatic patients
In clinical situations where the practitioner forms and fully documents the opinion that the patient’s symptoms dictate that colonoscopy is the most appropriate diagnostic procedure (this excludes screening) then item 32223 or 32233 can be billed. Claims under these items will be subject to increased oversight and review, particularly if larger claims than expected are observed.
How to use the items with new patients who have undergone previous colonoscopy
Patients whose care continues within one practice should have a certain history available to guide decision making regarding surveillance intervals. For new patients, practitioners should make reasonable efforts to establish a patient’s previous colonoscopy history. Once these items are established, the patients’ MBS claims history for those patients who do not require polypectomy will assist with this. The following case examples are provided to guide practitioners in the appropriate use of these new items.
Example 1 – New patient
A new patient is referred with advice that they had 2 polyps removed at their last colonoscopy but the pathology results and size is unknown. The practitioner may decide that 32227 is the most appropriate item to bill. This means that 1) no polyps were removed at this colonoscopy and 2) the patient can be recalled for a repeat colonoscopy in 5 years. Alternatively the lack of certain history, particularly around the type of polyp removed, may lead the clinician to believe that a shorter interval is appropriate and hence an item that corresponds with a higher risk category could be chosen, for instance item 32228. This establishes the patient’s Medicare claims history and is available for other practitioners if the patient moves. If in the future the patient has polyps removed which are adenomas then this will establish a new and possibly different previous history which may place the patient in a different risk category and item range.
Example 2 – New patient
For the same scenario as above, but where polyps are removed during the current colonoscopy, the practitioner would choose the B item that mirrors 32227 (ie 32237), as the assessment of patient history is the same. However advice to the patient about the appropriate interval for further colonoscopy will depend on the number, size and type of adenomas removed at this colonoscopy. This judgement will usually rely on the outcome of pathology testing and hence will not be available at the time of colonoscopy.
For audit purposes it is important to record the most appropriate item. In accordance with good practice, clinicians are required to maintain records that include pathology results which can be made available to the patient or other practitioners as required.
Hierarchy of items
Patients may fit several categories and the most appropriate fit is a matter for clinician judgement with the highest risk indicating what subsequent colonoscopy intervals are appropriate. The examples provided below show that the result of the histopathology will not lengthen the surveillance intervals (in the case of patient with FAP or Lynch) and may actually shorten the surveillance intervals (in the case of patient with FDR or SDR with CRC).
General guidance
“To the caecum” requirements for colonoscopy examinations do not apply to patients who have no caecum following right hemi colectomy or have an obstructed right sided tumour. For these patients the examination should be to the anastomosis or tumour.
Surveillance colonoscopy should be planned based on high-quality endoscopy in a well-prepared colon using most recent and previous procedure information when histology is known. Many patients > 80 years have little to gain from surveillance of adenomas given a 10-20 year lead-time for the progression of adenoma to cancer. The finding of serrated lesions may alter management. Small, pale, distal hyperplastic polyps only do not require follow-up.
General practitioners should ensure colonoscopy referral practices align with applicable NHMRC guidelines and the Royal Australian College of General Practitioners’ guidelines for preventive activities in general practice (the red book). When referring patients for a colonoscopy, general practitioners should ensure a complete patient history of any previous colonoscopy with histopathology result is provided to the clinician performing the investigation. In addition, general practitioners are urged to recommend biennial faecal occult blood test (FOBT) screening to age-appropriate patients. The National Bowel Cancer Screening Program (the Program) will be fully rolled out in Australia by 2020 by which time all 50-74 year old Australian residents will be invited to participate in biennial FOBT screening through the Program.
Failed preparation of the colon (item 32231)
Item 32231 is to be billed where a colonoscopy is unsatisfactory due to a failed preparation of the colon. Under these circumstances a second complete colonoscopy is payable. For example, a patient may be referred for a colonoscopy due to a positive FOBT test. The first colonoscopy examination has failed due to a poorly prepared colon but the caecum has been reached. Item 32231 is payable. The second colonoscopy examination is performed satisfactorily. Item 32222 is payable. If the caecum cannot be reached as this would cause risks to the patient, the most appropriate item to bill is sigmoidoscopy/colonoscopy item 32084.
It should be noted these services cannot be billed together for the same patient, same provider, on the same day during a single episode of sedation/anaesthesia.
Co-claiming restrictions
Colonoscopy services in the item range 32222 to 32231 and 32232 to 32241 cannot be billed together for the same patient, same provider, on the same day during a single episode of sedation/anaesthesia. Colonoscopy services in this item range cannot be billed with Sigmoidoscopy services in the item range 32081 – 32084 for the same patient, same provider, on the same day during a single episode of sedation/anaesthesia. Colonoscopy item 32241 cannot be co-claimed with item 32212 (treatment of radiation proctitis with formalin) same patient, same practitioner, same day during a single episode of sedation/anaesthesia.
Patient eligibility for colonoscopy services
The new structure of the colonoscopy items reflect the current evidence for the use of colonoscopy, including appropriate intervals between colonoscopies used in surveillance of patients who are at increased risk of developing colorectal cancer.
Patients seeking Medicare rebates for colonoscopy services 32222, 32225 to 32231 and 32232 will need to ensure that they are eligible for the service prior to proceeding with the procedure. MBS payments for these services are aligned with approved guidelines and algorithms on the appropriate screening and interval surveillance for colonoscopy.
For further information visit the Cancer Council Australia website.
The Department of Human Services will be able to confirm whether a colonoscopy service has been claimed through Medicare by an individual patient and the date of the service. It will also be able to confirm any restriction on the frequency of the item claimed which would prevent a rebate from being paid if the service was provided again within the restricted period. Patients can seek clarification from the Department of Human Services by calling 132 011.
Patients can also access their own claiming history with a My Health Record or by establishing a Medicare online account through myGov or the Express Plus Medicare mobile app.
Further information about these services can be found on the Department of Human Services website.
In the second year of operation (from March 2019) practitioners providing colonoscopy services will be able to call Medicare on a dedicated call line to check the patient’s claiming history and ensure time restrictions do not apply to the proposed service. The patient’s Medicare card number will be required together with the range of item numbers to be checked. For example, the new item numbers for colonoscopy services are in the range 32222 to 32231 and 32232 to 32241. The operator will interrogate the patient’s claiming history and provide advice on any claim paid for a colonoscopy service within the range of items specified and the date of the service. For new patients who are unsure of past colonoscopy history this advice will assist the practitioner to determine the correct item to bill for the proposed service.
Alternatively, the Health Professionals Online System (HPOS) is a secure way for health professionals and administrators to check if a patient is eligible for a Medicare benefit for a specific item on the date of the proposed service. However, this system will only return advice that the service is payable or not payable on the proposed service date. It will not return full advice on when the last service was provided or when the patient will become eligible for the service again. For example, if the service has a 3 year restriction and the last service was provided in November 2017, the advice will be that the item is not payable if the proposed service date is before November 2020. It will not advise that the last service was provided in November 2017.
Further information about this service can be found on the Department of Human Services website.
All patients who require a colonoscopy will receive a service. However, MBS rebates will not be payable for services which do not meet the clinical indications and the item requirements for a colonoscopy or a repeat colonoscopy where the interval is specified in the item. Practitioners should ensure that their practice conforms to the approved clinical guidelines.
In this section
- Current Factsheets
- All Fact Sheets
- Changes to MBS items for orthopaedic surgery services
- 1 January 2025 pathology MBS changes
- 1 July 2023 pathology MBS changes
- 1 July 2024 pathology MBS changes
- 1 March 2021 fee increase for item 30630
- 1 March 2025 Pathology Changes - Amendment of MBS items 73296 and 73297 for BRCA-related breast, ovarian, fallopian tube or primary peritoneal cancer due to family history
- 1 November 2023 pathology MBS changes
- 1 November 2024 pathology MBS changes
- 17p chromosomal deletion testing for chronic lymphocytic leukaemia or small lymphocytic lymphoma – MBS item 73343
- Abdominal magnetic resonance imaging for rare genetic conditions associated with risk of renal tumours – new items for 1 July 2024
- Accreditation for SARS-CoV-2 Testing
- Acupuncture Services MBS item changes
- Allied Health Case Conferencing
- Alternative positron emission tomography (PET) item for use during gallium-67 supply disruptions
- Ambulatory blood pressure monitoring for diagnosis of hypertension
- Amended MBS mental health and wellbeing telehealth items
- Amendment to existing skin excision and skin flap items
- Amendment to MBS item 51071 for spinal surgery
- Anaesthesia Age Modifier Items
- Appropriate Billing of MBS Item 13950
- Assessment for a COVID-19 oral anti-viral medication
- Autologous Fat Grafting
- Benign prostatic hyperplasia (BPH): introduction of two new Medicare Benefits Schedule (MBS) items and removal of four outdated MBS items
- Blood Product Services
- Bulk Billing in General Practice from 1 November 2023
- Capital Sensitivity exemption changes to diagnostic imaging services
- Capital sensitivity exemption changes to diagnostic imaging services
- Cardiac implantable loop recorder (ILR) devices - new MBS items for remote monitoring
- Cardiac magnetic resonance imaging (MRI) for myocarditis associated with mRNA COVID-19 vaccination - item continuation
- Cardiac magnetic resonance imaging (MRI) for myocarditis associated with mRNA COVID-19 vaccination - item continuation
- Cardiac magnetic resonance imaging (MRI) for myocarditis associated with mRNA COVID-19 vaccination
- Cardiac magnetic resonance imaging for myocarditis from 1 January 2025
- Cardiac Services T8 Item amendments
- Cardiac Stress Echocardiography and Stress Myocardial Perfusion Studies (MPS) - Claiming Information Guide
- Cardiothoracic surgery MBS item changes
- Cardiothoracic surgery – Amended item for complex replacement or repair of aortic arch
- Cessation of Approved Collection Centre pathology measures
- Cessation of the temporary Medicare Benefits Schedule (MBS) items for nuclear medicine factsheet
- Change to Botulinum Toxin Injection Item 18365 Factsheet
- Change to MBS medical perfusion (item 22060) factsheet
- Changes for diagnostic imaging services factsheet
- Changes to Anaesthesia MBS items
- Changes to Category 7 – Cleft and Craniofacial Services
- Changes to Colonoscopy services
- Changes to emergency medicine services
- Changes to in and out of hospital benefit for plastic and reconstructive surgery services
- Changes to MBS - 26 February 2021
- Changes to MBS anaesthesia items
- Changes to MBS benefit for eyelid reconstruction item 45614 from 1 November 2024
- Changes to MBS colonoscopy items factsheet
- Changes to MBS heart health assessment items 699 and 177
- Changes to MBS heart health assessment items factsheet
- Changes to MBS item 72814 for Programmed Cell Death Ligand (PD-L1) testing from 1 September 2023
- Changes to MBS items 15900 and 31516 factsheet
- Changes to MBS items 30196 and 30202
- Changes to MBS items 37207 and 37208 factsheet
- Changes to MBS items for breast biopsy services factsheet
- Changes to MBS Items for colonoscopy services factsheet
- Changes to MBS items for intensive care services
- Changes to MBS varicose vein items
- Changes to Obstetric MRI items factsheet
- Changes to psychiatry services from 1 March 2024
- Changes to supervision requirements for nuclear medicine imaging services from 1 July 2024
- Changes to the MBS - 26 February 2021
- Changes to the Medicare Benefits Schedule for radiation therapy items
- Changes to thoracic surgery Medicare Benefits Schedule (MBS) items
- Chemotherapeutic Procedures Factsheet
- Childhood Access to Anaesthesia Services Factsheet
- Chronic disease management by consultant physicians
- Claiming Microbiology Tests for SARS-CoV-2 (COVID-19) factsheet
- Clarifying clinical intent of spinal decompression items (MBS items 51011 to 51015)
- Clarifying MBS Items that are Hospital Only Services
- Clarifying the clinical intent of partial rhinoplasty (MBS item 45632)
- Clinically suspected melanoma item fee changes to include 2022 indexation
- Co-claiming limitations of subsequent attendance items with certain Group T8 surgical operations
- Co-claiming of subsequent attendance items with group T8 surgical operations.
- Colorectal Surgery MBS Item Changes
- Complex neurodevelopmental disorder and eligible disability changes to MBS items
- Continuous nerve blockade for post-operative pain management from 1 March 2025
- COVID-19 high risk group temporary exemption from established relationship requirement
- COVID-19 Temporary MBS Telehealth Services
- Cryoablation for biopsy-confirmed renal cell carcinoma - New MBS item
- CT Angiography of Pulmonary Arteries and Minor Changes
- Deep brain stimulation (DBS) - New MBS item 40863 for remote programming of a neurostimulator
- Determining lesion size for MBS items 31356 to 31388 selection
- Device agnostic transcatheter mitral valve repair, TMVr, by transvenous or transeptal techniques in patients with degenerative-primary mitral valve regurgitation
- Diagnostic imaging capital sensitivity 1 May 2022 exemption changes factsheet
- Diagnostic Imaging Medicare Benefits Schedule (MBS) Item and Rule Changes
- Diagnostic Imaging Medicare Benefits Schedule (MBS) item changes for 1 July 2022
- Diagnostic imaging Medicare Benefits Schedule (MBS) item changes for 1 November 2021
- Diagnostic Imaging Services Table - Changes commencing from 1 July 2023
- Diagnostic Imaging Services Table - Changes to musculoskeletal ultrasound supervision requirements
- Diagnostic Imaging Services Table - New MBS item for whole body MRI scan
- Diagnostic Imaging Services Table – Changes from 1 November 2024
- Eligibility for magnetic resonance imaging (MRI) equipment changes from 1 July 2025
- Endoscopic Mucosal Resection (EMR) – minor amendment to MBS Item 32230
- Endoscopic Mucosal Resection (EMR) from 1 November 2021
- Endoscopic Mucosal Resection and related colonoscopy item changes for 1 July 2024
- Ensuring Appropriate Use of Neurosurgery and Neurology Services
- Ensuring Appropriate Use of Neurosurgery and Neurology Services
- Exercise electrocardiogram (ECG) stress testing – New item
- Expanded patient access to mastopexy (MBS item 45558)
- Expanded patient access to Transcatheter occlusion for the Left Atrial Appendage
- Expanding patient access to Cleft Dental Services
- Extended Medicare Safety Net (EMSN) caps on new ultrasound items
- EXTENDING MENTAL HEALTH SUPPORT FOR AGED CARE RESIDENTS DURING COVID-19
- Extension of COVID Pathology Items
- Extension of MBS Item 32221 for removal or revision of an artificial bowel sphincter
- Extension of SARS-CoV-2 (COVID-19) Laboratory Testing Items
- Extension of temporary pathology items for SARS-CoV-2 (COVID-19) and other respiratory pathogens
- Extension of temporary Pathology items for SARS-CoV-2 (COVID-19) and other respiratory pathogens
- Extension of the SARS-CoV-2 (COVID-19) Pathology Items
- Extracorporeal Magnetic Innervation (ExMI) factsheet
- Extracorporeal photopheresis (ECP) for chronic graft versus host disease (cGVHD)
- Factsheet Change to item 18361
- Factsheet Changes to Nuclear Medicine items
- Factsheet ECP for the Treatment of CTCL
- Factsheet for Additional 10 MBS Mental Health Sessions
- Factsheet for changes to item 73343 to enable testing for acalabrutinib
- Factsheet for MBS item 69501
- Factsheet for MBS item 73295
- Factsheet for MBS item 73344
- Factsheets for 2018
- Factsheets for 2019
- Factsheets for 2020
- Factsheets for 2021
- Factsheets for 2022
- Factsheets for 2023
- Family and Carer Participation under the Better Access Initiative
- Fee loading for bulk billed consultant psychiatrist telehealth attendance - New MBS item 294
- Full versus Partial Medicare-eligible MRI machines in the Diagnostic Imaging Services Table
- Gallium-67 - New temporary diagnostic imaging MBS item
- General Surgery Services changes factsheets
- Genetic testing changes for Pharmaceutical Benefits Scheme (PBS) immunotherapy
- Genetic testing for alpha thalassaemia - amendment to Pathology MBS item 73410
- Genetic testing for BRCA1/2 gene variants for patients with metastatic castration-resistant prostate cancer
- Genetic Testing for Childhood Syndromes
- Genetic Testing for Hydatidiform Moles
- Genetic testing for major fetal structure abnormalities
- Genetic testing for neuromuscular disorders - new pathology MBS items 73422 to 73428
- Genetic testing for neurotrophic receptor tyrosine kinase (NTRK) fusion in patients with locally advanced or metastatic solid tumours
- Genetic testing for people with multiple myeloma and chronic lymphocytic leukaemia
- Geriatrician or consultant physician assessment and management plans
- Group Therapy MBS Changes under the Better Access Initiative
- Gynaecology MBS item changes
- Gynaecology – minor changes
- Haemorrhoid treatments – changes to items 32135 and 32139
- Heart health assessment items
- Implementation of MBS Review Taskforce recommendations to optometry items - 1 March 2025
- Inclusion of communication time when claiming time-tiered MBS items
- Inpatient telehealth psychiatry services
- Insertion of marker clip(s) following a breast biopsy
- Intracranial aneurysm item – Amended item
- Intravascular ultrasound guided coronary stent insertion – New item
- Introducing a New Stroboscopy MBS Item
- Introduction of 6 minute minimum time for MBS Level B GP consultations
- Introduction of new Level E consultation items lasting 60 minutes or more
- Leadless permanent cardiac pacemaker new and amended items
- Leadless permanent cardiac pacemaker – Amended items
- Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
- Magnetic Resonance Imaging (MRI) equipment MBS eligibility changes
- MBS COVID-19 Management Support Service
- MBS funded investigations for sleep disorders – current professional guidelines
- MBS Support for People in COVID-19 Hotspots
- MBS Telehealth Services
- MBS Telehealth Services from 1 July 2022
- MBS Telehealth Services from January 2022
- Measurement of Faecal Calprotectin as a Marker of Bowel Inflammation
- Medicare Benefits Schedule (MBS) item 42739 factsheet
- Medicare Compliance and Telehealth Services
- Medicare Indexation of Diagnostic Imaging Services Factsheet
- Medicare Indexation Schedule
- Medicare Safety Net Arrangement - 1 January 2021
- Medicare Safety Net Arrangement - 1 January 2022
- Medicare Safety Net Arrangements - 1 January 2019
- Medicare Safety Net Arrangements – 1 January 2023
- Medicare Safety Net Arrangements – 1 January 2024
- Medicare Safety Net Arrangements – 1 January 2025
- Medicare Safety Net Thresholds from 1 January 2019
- Medicare Safety Net Thresholds from 1 January 2020
- Medicare Support for COVID-19 Vaccinations
- Medicare Support in Response to Omicron - GP and Other Medical Officer (OMP) Longer Telephone Consultation.
- Melanoma excision services MBS item changes
- Mental Health Case Conferencing items
- Mental Health Services for Bushfire Response
- METex14sk testing to access tepotinib on the PBS - new item 73436
- Minimally invasive ventral rectopexy – ongoing item 32118
- Minor change to colorectal surgery MBS item 32006 for left hemicolectomy
- Minor changes to MBS Items for Orthopaedic Surgery
- Minor changes to sleep study items 12205 and 12207 factsheet
- Minor changes to spinal surgery items factsheet
- Minor changes to thoracic medicine items.
- Modernising Cardiac Surgical Services
- MSAC Application 1523.1 - Transluminal insertion, management, and removal of an intravascular microaxial blood pump (ImpellaŽ), for patients requiring mechanical circulatory support Quick Reference Guide
- Multidisciplinary case conference items for complex neurodevelopmental disorders and eligible disabilities
- National Cervical Screening Program (NCSP) MBS item amendments
- Neuromyelitis Optica Testing
- New and amended Medicare Benefits Schedule (MBS) items for Transcatheter Aortic Valve Implantation (TAVI)
- New arrangements for GP Residential Aged Care Facility (RACF) services
- New item for homologous recombination deficiency testing of patients with ovarian, fallopian tube or peritoneal cancer
- New items using blue-light cystoscopy (BLC) with hexaminolevulinate (HAL) for improved diagnosis, treatment and management of non-muscle invasive bladder cancer (NMIBC)
- New Items – Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy
- New Items – Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy
- New Items – Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy
- New MBS item 30175 for abdominoplasty
- New MBS Item for micro bypass glaucoma surgery (MBGS)
- New MBS Item for mobile provision of skeletal x-ray to patients within residential aged care facilities factsheet
- New MBS item for vertebroplasty
- New MBS items for Transcatheter Mitral Valve repair
- New MBS telehealth items for the remote programming of auditory implants and/or sound processors
- New Medicare Benefits Schedule (MBS) item for percutaneous transcatheter delivery of a dual filter Cerebral Embolic Protection Device (CEP) during transcatheter aortic valve implantation (TAVI)
- New Medicare Benefits Schedule (MBS) item for prostate biopsy guided by magnetic resonance imaging (MRI) factsheet
- New Medicare Benefits Schedule (MBS) item for surgical correction of congenital ear deformities
- New Medicare Benefits Schedule (MBS) Items for contrast-enhanced magnetic resonance imaging (MRI) of the liver
- New Medicare Benefits Schedule (MBS) items for FDG positron emission tomography (PET) for the evaluation of breast cancer factsheet
- New Medicare Benefits Schedule (MBS) items for magnetic resonance imaging (MRI) for breast cancer factsheet
- New Medicare Benefits Schedule (MBS) items for obstetric magnetic resonance imaging (MRI) of patients at ≥ 18 weeks gestation with suspected fetal central nervous system abnormality
- New temporary MBS item 32118 for minimally invasive ventral mesh rectopexy
- New temporary Medicare Benefits Schedule (MBS) items for nuclear medicine factsheet
- Nicotine and Smoking Cessation Counselling MBS Services
- Nuclear medicine item 61485 - One-off schedule fee increase
- Nurse practitioner MBS changes
- Nurse practitioner MBS changes from 1 July 2024
- Orthopaedic Surgery - minor changes
- Orthopaedic surgery amendments to eight MBS items
- Orthopaedic surgery – minor amendment to item 49706
- Orthopaedic Surgery – New and amended MBS items
- Other Medical Practitioner and General Practitioner Medicare Benefits Schedule (MBS) items administrative changes
- Otolaryngology and diagnostic audiology changes commencing 1 July 2024
- Otolaryngology, head and neck surgery MBS changes
- Otolaryngology, head and neck surgery MBS changes commencing 1 November 2023
- Paediatric Surgery MBS item changes
- Pain Management Services Changes
- Participating midwives MBS changes
- Participating Midwives MBS Item Changes
- Pathology Medicare Benefits Schedule (MBS) item changes for 1 July 2022
- Pathology Medicare Benefits Schedule (MBS) item changes for 1 September 2022
- Personal attendance for musculoskeletal ultrasound and personal supervision for nuclear medicine imaging services
- Plastic and reconstructive surgery MBS changes
- Plastics and reconstructive surgery MBS changes commencing 1 November 2023
- Point-of-care HbA1c testing for patients with diagnosed diabetes
- Pre-implantation Genetic Testing (PGT)
- Previous Years Factsheets
- Privacy Checklist for Telehealth Services
- Programmed Cell Death Ligand (PD-L1) testing changes to pathology MBS item 72814
- Relative Value Guide – changes to cell salvage item 22002
- Remote reprogramming of a neurostimulator for the management of chronic pain
- Removal of age restriction for glucocorticoid injections of keloid lesions (MBS Item 30210)
- Removal of legislated collaborative arrangements
- Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy – updated FAQ
- Repetitive Transcranial Magnetic Stimulation therapy on the MBS
- Replication of three items into the Relative Value Guide (RVG) for Anaesthesia
- Requests for diagnostic imaging services versus referrals for other services under Medicare
- Rural Bulk Billing Incentive Changes
- Safe and Best Practice Cardiac Imaging Services
- SARS-CoV-2 (COVID-19) and other respiratory pathogens pathology items
- Sentinel Lymph Node Biopsy (SLNBx) for intermediate thickness Melanoma
- Single operator, single use peroral cholangiopancreatoscopy for the diagnosis of indeterminate biliary strictures and removal of difficult biliary stones
- Spinal surgery Medicare Benefits Schedule item changes to exclude use for Vertebral Body Tethering (VBT)
- Split of MBS item 45626 for correction of entropion or ectropion due to trachoma or non-trachomatous causes factsheet
- Streamlining First Nations Australians’ access to allied health services
- Substitute positron emission tomography (PET) item for use during thallium-201 supply shortage
- Suspension of substitute Medicare Benefits Schedule (MBS) items for nuclear medicine
- TAVI standby cardiac surgeon amendments - items 90300, 38514, 38522 for low and intermediate surgical risk patients - Quick Reference Guide
- Telehealth MBS eligibility for COVID-19 positive patients
- Telehealth Services Provided by GPs and Non-Specialist Medical Practitioners to Patients in Rural and Remote Areas
- Temporary COVID-19 MBS Telehealth Services – specialist inpatient services
- Temporary COVID-19 Allied Health Support Services and GP/OMP Services for Aged Care Residents.
- Temporary nuclear medicine items 61470 and 61477 – item continuation and one-off fee increase
- Therapeutic nuclear medicine MBS changes
- Thoracic medicine items – minor updates
- Thoracic surgery MBS changes
- Three new items relating to plastic and reconstructive surgery for nurse practitioners
- Transcatheter aortic valve implantation - Amended items
- Transcatheter aortic valve implantation (TAVI) items - complete service advice
- Transcatheter Aortic Valve Implantation (TAVI) – new and amended services
- Upcoming changes to MBS items - Eating Disorders
- Updates to the Medicare Benefits Schedule for radiation therapy items from 1 November 2024
- Upper eyelid reduction surgery - Changes to MBS item 45617
- Urology Services Factsheet
- Varicose vein MBS item changes
- Verbal assignment of benefit arrangements for telehealth services